Systemic toll-like receptor ligands modify B-cell responses in human inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 17, Issue 1, 2011, Pages 298-307

  McDonnell, Marie ^a   Liang, Yanmei ^b   Noronha, Ansu ^a   Coukos, Jennifer ^a   Kasper, Dennis L ^c   Farraye, Francis A ^a   Ganley Leal, Lisa M ^b  

^a BOSTON MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

B cell; endotoxin; HMGB1; human; inflammatory bowel disease; Toll like receptor

Indexed keywords

CD36 ANTIGEN; ENDOTOXIN; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

ARTICLE; B LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; ENDOTOXEMIA; EX VIVO STUDY; HIGH MOBILITY GROUP BOX DOMAIN; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VIVO STUDY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ULCERATIVE COLITIS;

B-LYMPHOCYTES; COLITIS, ULCERATIVE; CROHN DISEASE; CYTOKINES; FLOW CYTOMETRY; HMGB1 PROTEIN; HUMANS; LIGANDS; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; TOLL-LIKE RECEPTORS;

EID: 78650077214     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21424     Document Type: Article

References (50)

1. Knight P, Campbell BJ, Rhodes JM,. Host-bacteria interaction in inflammatory bowel disease. Br Med Bull. 2008; 88: 95-113.
2. Subramanian S, Campbell BJ, Rhodes JM,. Bacteria in the pathogenesis of inflammatory bowel disease. Curr Opin Infect Dis. 2006; 19: 475-484.
3. Karlsson H, Hessle C, Rudin A,. Innate immune responses of human neonatal cells to bacteria from the normal gastrointestinal flora. Infect Immun. 2002; 70: 6688-6696.
4. Aoki K,. A study of endotoxemia in ulcerative colitis and Crohn's disease. II. Experimental study. Acta Med Okayama. 1978; 32: 207-216. (Pubitemid 9007796)
5. Pasternak BA, D'Mello S, Jurickova II, et al. Lipopolysaccharide exposure is linked to activation of the acute phase response and growth failure in pediatric Crohn's disease and murine colitis. Inflamm Bowel Dis. 2010; 16: 856-859.
6. Pastor Rojo O, Lopez San Roman A, Albeniz Arbizu E, et al. Serum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007; 13: 269-277.
7. Lockhart PB, Brennan MT, Sasser HC, et al. Bacteremia associated with toothbrushing and dental extraction. Circulation. 2008; 117: 3118-3125.
8. Gutierrez A, Frances R, Amoros A, et al. Cytokine association with bacterial DNA in serum of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2009; 15: 508-514.
9. Gardiner KR, Halliday MI, Barclay GR, et al. Significance of systemic endotoxaemia in inflammatory bowel disease. Gut. 1995; 36: 897-901.
10. Lukacova M, Barak I, Kazar J,. Role of structural variations of polysaccharide antigens in the pathogenicity of Gram-negative bacteria. Clin Microbiol Infect. 2008; 14: 200-206.
11. Coats SR, Reife RA, Bainbridge BW, et al. Porphyromonas gingivalis lipopolysaccharide antagonizes Escherichia coli lipopolysaccharide at Toll-like receptor 4 in human endothelial cells. Infect Immun. 2003; 71: 6799-6807.
12. Bianchi ME, Manfredi AA,. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev. 2007; 220: 35-46.
13. Caradonna L, Amati L, Magrone T, et al. Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: biological and clinical significance. J Endotoxin Res. 2000; 6: 205-214.
14. Klune JR, Dhupar R, Cardinal J, et al. HMGB1: endogenous danger signaling. Mol Med. 2008; 14: 476-484.
15. Pisetsky DS, Erlandsson-Harris H, Andersson U,. High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease. Arthritis Res Ther. 2008; 10: 209.
16. Devaraj S, Dasu MR, Park SH, et al. Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes. Diabetologia. 2009; 52: 1665-1668.
17. Tian J, Avalos AM, Mao SY, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol. 2007; 8: 487-496.
18. Yanai H, Ban T, Wang Z, et al. HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature. 2009; 462: 99-103.
19. Bianchi ME,. HMGB1 loves company. J Leukoc Biol. 2009; 86: 573-576.
20. Linskens RK, Huijsdens XW, Savelkoul PH, et al. The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics. Scand J Gastroenterol Suppl. 2001; 29-40.
21. Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006; 444: 1027-1031.
22. Ley RE, Turnbaugh PJ, Klein S, et al. Microbial ecology: human gut microbes associated with obesity. Nature. 2006; 444: 1022-1023.
23. Noronha AM, Liang Y, Hetzel JT, et al. Hyperactivated B cells in human inflammatory bowel disease. J Leukoc Biol. 2009; 86: 1007-1016.
24. Jagannathan M, Hasturk H, Liang Y, et al. TLR cross-talk specifically regulates cytokine production by B cells from chronic inflammatory disease patients. J Immunol. 2009; 183: 7461-7470.
25. Shin H, Zhang Y, Jagannathan M, et al. B cells from periodontal disease patients express surface Toll-like receptor 4. J Leukoc Biol. 2009; 85: 648-655.
26. Ungaro R, Fukata M, Hsu D, et al. A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am J Physiol Gastrointest Liver Physiol. 2009; 296: G1167-1179.
27. Kim JH, Kim SJ, Lee IS, et al. Bacterial endotoxin induces the release of high mobility group box 1 via the IFN-beta signaling pathway. J Immunol. 2009; 182: 2458-2466.
28. Busconi L, Bauer JW, Tumang JR, et al. Functional outcome of B cell activation by chromatin immune complex engagement of the B cell receptor and TLR9. J Immunol. 2007; 179: 7397-7405.
29. Stewart CR, Stuart LM, Wilkinson K, et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol. 2010; 11: 155-161.
30. Wang Q, McLoughlin RM, Cobb BA, et al. A bacterial carbohydrate links innate and adaptive responses through Toll-like receptor 2. J Exp Med. 2006; 203: 2853-2863.
31. Dasari P, Nicholson IC, Hodge G, et al. Expression of Toll-like receptors on B lymphocytes. Cell Immunol. 2005; 236: 140-145.
32. Shibolet O, Podolsky DK,. TLRs in the gut. IV. Negative regulation of Toll-like receptors and intestinal homeostasis: addition by subtraction. Am J Physiol Gastrointest Liver Physiol. 2007; 292: G1469-1473.
33. Lagrange PH, Mackaness GB,. Effects of bacterial lipopolysaccharide on the induction and expression of cell-mediated immunity. II. Stimulation of the efferent arc. J Immunol. 1975; 114: 447-451.
34. Biswas SK, Lopez-Collazo E,. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol. 2009; 30: 475-487.
35. Coats SR, Pham TT, Bainbridge BW, et al. MD-2 mediates the ability of tetra-acylated and penta-acylated lipopolysaccharides to antagonize Escherichia coli lipopolysaccharide at the TLR4 signaling complex. J Immunol. 2005; 175: 4490-4498.
36. Lundberg A, Wikberg LA, Ilonen J, et al. Lipopolysaccharide-induced immune responses in relation to the TLR4(Asp299Gly) gene polymorphism. Clin Vaccine Immunol. 2008; 15: 1878-1883.
37. Franchimont D, Vermeire S, El Housni H, et al. Deficient host-bacteria interactions in inflammatory bowel disease? The Toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut. 2004; 53: 987-992.
38. Rott LS, Briskin MJ, Butcher EC,. Expression of alpha4beta7 and E-selectin ligand by circulating memory B cells: implications for targeted trafficking to mucosal and systemic sites. J Leukoc Biol. 2000; 68: 807-814.
39. Kunkel EJ, Kim CH, Lazarus NH, et al. CCR10 expression is a common feature of circulating and mucosal epithelial tissue IgA Ab-secreting cells. J Clin Invest. 2003; 111: 1001-1010.
40. Pabst O, Ohl L, Wendland M, et al. Chemokine receptor CCR9 contributes to the localization of plasma cells to the small intestine. J Exp Med. 2004; 199: 411-416.
41. Lo CG, Lu TT, Cyster JG,. Integrin-dependence of lymphocyte entry into the splenic white pulp. J Exp Med. 2003; 197: 353-361.
42. Lanzarotto F, Carpani M, Chaudhary R, et al. Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin. Drugs. 2006; 66: 1179-1189.
43. Svennerholm AM, Steele D,. Microbial-gut interactions in health and disease. Progress in enteric vaccine development. Best Pract Res Clin Gastroenterol. 2004; 18: 421-445.
44. Suzuki K, Fagarasan S,. How host-bacterial interactions lead to IgA synthesis in the gut. Trends Immunol. 2008; 29: 523-531.
45. Nikolajczyk BS,. B cells as under-appreciated mediators of non-auto-immune inflammatory disease. Cytokine. 2010; 50: 234-242.
46. Braun J, Wei B,. Body traffic: ecology, genetics, and immunity in inflammatory bowel disease. Annu Rev Pathol. 2007; 2: 401-429.
47. Browning BL, Huebner C, Petermann I, et al. Has Toll-like receptor 4 been prematurely dismissed as an inflammatory bowel disease gene? Association study combined with meta-analysis shows strong evidence for association. Am J Gastroenterol. 2007; 102: 2504-2512.
48. Baumgart DC, Thomas S, Przesdzing I, et al. Exaggerated inflammatory response of primary human myeloid dendritic cells to lipopolysaccharide in patients with inflammatory bowel disease. Clin Exp Immunol. 2009; 157: 423-436.
49. Shen X, Shi R, Zhang H, et al. The Toll-like receptor 4 D299G and T399I polymorphisms are associated with Crohn's disease and ulcerative colitis: a meta-analysis. Digestion. 2010; 81: 69-77.
50. Vanderpool C, Yan F, Polk DB,. Mechanisms of probiotic action: implications for therapeutic applications in inflammatory bowel diseases. Inflamm Bowel Dis. 2008; 14: 1585-1596.